Denali Therapeutics Inc.
US ˙ NasdaqGS ˙ US24823R1059

SecurityDNLI / Denali Therapeutics Inc.
InstitutionCitigroup Inc
Latest Disclosed Ownership39,278 shares
Latest Disclosed Value $ 754,138
Citigroup Inc ownership in DNLI / Denali Therapeutics Inc.

On May 11, 2026 - Citigroup Inc filed a 13F-HR form disclosing ownership of 39,278 shares of Denali Therapeutics Inc. (US:DNLI) valued at $754,138 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 30,945 shares of Denali Therapeutics Inc.. This represents a change in shares of 26.93% during the quarter. The current value of the position is $791,059 USD.

Citigroup Inc has a history of taking positions in derivatives of the underlying security (DNLI) in the form of stock options. The firm currently holds call options representing 30,000 of underlying shares valued at $576,000 USD and put options representing 30,000 of underlying shares valued at $576,000 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DNLI / Denali Therapeutics Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-11 2026-03-31 13F DENALI THERAPEUTICS COM 24823R105 39,278 8,333 26.93 754 47.84 0.0003
2026-02-13 2025-12-31 13F DENALI THERAPEUTICS COM 24823R105 30,945 16,009 107.18 511 136.11 0.0002
2025-11-10 2025-09-30 13F DENALI THERAPEUTICS COM 24823R105 14,936 -61,379 -80.43 217 -79.76 0.0001
2025-08-11 2025-06-30 13F DENALI THERAPEUTICS COM 24823R105 76,315 -117,689 -60.66 1,068 -59.54 0.0005
2025-05-12 2025-03-31 13F DENALI THERAPEUTICS COM 24823R105 194,004 27,298 16.37 2,637 -22.37 0.0013
2025-02-12 2024-12-31 13F DENALI THERAPEUTICS COM 24823R105 166,706 71,992 76.01 3,397 23.12 0.0020
2024-11-12 2024-09-30 13F DENALI THERAPEUTICS COM 24823R105 94,714 50,163 112.60 2,759 166.83 0.0016
2024-08-12 2024-06-30 13F DENALI THERAPEUTICS COM 24823R105 44,551 -337,865 -88.35 1,034 -86.82 0.0007
2024-05-10 2024-03-31 13F DENALI THERAPEUTICS COM 24823R105 382,416 241,140 170.69 7,847 158.89 0.0052
2024-02-09 2023-12-31 13F DENALI THERAPEUTICS COM 24823R105 141,276 2,967 2.15 3,032 6.24 0.0021
2023-12-06 2023-09-30 13F/A-1 DENALI THERAPEUTICS COM 24823R105 138,309 30,282 28.03 2,853 -10.48 0.0021
2023-11-09 2023-09-30 13F DENALI THERAPEUTICS COM 24823R105 138,309 30,282 2,853 0.0009
2023-08-10 2023-06-30 13F DENALI THERAPEUTICS COM 24823R105 108,027 -100,313 -48.15 3,188 -33.60 0.0021
2023-05-11 2023-03-31 13F DENALI THERAPEUTICS COM 24823R105 208,340 80,220 62.61 4,800 34.72 0.0034
2023-02-09 2022-12-31 13F DENALI THERAPEUTICS COM 24823R105 128,120 -64,522 -33.49 3,563 -39.74 0.0028
2022-11-10 2022-09-30 13F DENALI THERAPEUTICS COM 24823R105 192,642 80,828 72.29 5,913 79.67 0.0042
2022-08-10 2022-06-30 13F DENALI THERAPEUTICS COM 24823R105 111,814 76,430 216.00 3,291 189.19 0.0024
2022-05-12 2022-03-31 13F DENALI THERAPEUTICS COM 24823R105 35,384 -84,997 -70.61 1,138 -78.80 0.0007
2022-02-10 2021-12-31 13F DENALI THERAPEUTICS COM 24823R105 120,381 11,356 10.42 5,369 -2.38 0.0029
2021-11-10 2021-09-30 13F DENALI THERAPEUTICS COM 24823R105 109,025 43,778 67.10 5,500 7.46 0.0032
2021-08-10 2021-06-30 13F DENALI THERAPEUTICS COM 24823R105 65,247 -4,527 -6.49 5,118 28.46 0.0031
2021-05-13 2021-03-31 13F DENALI THERAPEUTICS COM 24823R105 69,774 52,179 296.56 3,984 170.28 0.0026
2021-02-11 2020-12-31 13F DENALI THERAPEUTICS COM 24823R105 17,595 10,651 153.38 1,474 491.97 0.0009
2020-11-12 2020-09-30 13F DENALI THERAPEUTICS COM 24823R105 6,944 -42,920 -86.07 249 -79.34 0.0002
2020-08-12 2020-06-30 13F DENALI THERAPEUTICS COM 24823R105 49,864 12,000 31.69 1,205 81.75 0.0009
2020-05-12 2020-03-31 13F DENALI THERAPEUTICS COM 24823R105 37,864 20,342 116.09 663 117.38 0.0006
2020-02-12 2019-12-31 13F DENALI THERAPEUTICS COM 24823R105 17,522 -60,995 -77.68 305 -74.65 0.0002
2019-11-08 2019-09-30 13F DENALI THERAPEUTICS COM 24823R105 78,517 14,034 21.76 1,203 -10.16 0.0010
2019-08-12 2019-06-30 13F DENALI THERAPEUTICS COM 24823R105 64,483 52,480 437.22 1,339 379.93 0.0011
2019-05-13 2019-03-31 13F DENALI THERAPEUTICS COM 24823R105 12,003 -77,311 -86.56 279 -84.88 0.0003
2019-02-12 2018-12-31 13F DENALI THERAPEUTICS COM 24823R105 89,314 76,458 594.73 1,845 561.29 0.0019
2018-11-13 2018-09-30 13F DENALI THERAPEUTICS COM 24823R105 12,856 10,429 429.71 279 654.05 0.0002
2018-08-10 2018-06-30 13F DENALI THERAPEUTICS COM 24823R105 2,427 132 5.75 37 -17.78 0.0000
2018-05-11 2018-03-31 13F DENALI THERAPEUTICS COM 24823R105 2,295 2,295 45 0.0000
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-11 2026-03-31 13F DENALI THERAPEUTICS COM Call 30,000 576 n/a n/a n/a
2024-11-12 2024-09-30 13F DENALI THERAPEUTICS COM Call 0 -100.00 0 -100.00 n/a n/a n/a
2024-08-12 2024-06-30 13F DENALI THERAPEUTICS COM Call 59,900 1,391 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-05-11 2026-03-31 13F DENALI THERAPEUTICS COM Put 30,000 576 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.